Announcement • Apr 24
Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2026 Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2026, at 15:30 China Standard Time. Location: The Company Headquarters' Meeting Room, Taizhou, Zhejiang China New Risk • Apr 24
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 41% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Announcement • Mar 31
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Announcement • Dec 31
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.09 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.20 (up from CN¥0.09 in 3Q 2024). Revenue: CN¥719.5m (up 7.9% from 3Q 2024). Net income: CN¥71.4m (up 124% from 3Q 2024). Profit margin: 9.9% (up from 4.8% in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 23
Second quarter 2025 earnings released: EPS: CN¥0.18 (vs CN¥0.035 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.18 (up from CN¥0.035 in 2Q 2024). Revenue: CN¥808.1m (up 40% from 2Q 2024). Net income: CN¥63.3m (up 399% from 2Q 2024). Profit margin: 7.8% (up from 2.2% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Buy Or Sell Opportunity • Jun 04
Now 23% undervalued Over the last 90 days, the stock has risen 37% to CN¥24.89. The fair value is estimated to be CN¥32.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 265% in the next 2 years. New Risk • Jun 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Declared Dividend • Jun 02
Dividend of CN¥0.05 announced Dividend of CN¥0.05 is the same as last year. Ex-date: 6th June 2025 Payment date: 6th June 2025 Dividend yield will be 0.2%, which is lower than the industry average of 1.9%. Payout Ratios Payout ratio: 17%. Cash payout ratio: 19%. Reported Earnings • Apr 18
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.16 (up from CN¥0.08 in FY 2023). Revenue: CN¥2.63b (up 4.1% from FY 2023). Net income: CN¥55.9m (up 104% from FY 2023). Profit margin: 2.1% (up from 1.1% in FY 2023). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 47%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • Apr 18
Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2025 Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2025, at 15:30 China Standard Time. Location: The Company Headquarters' Meeting Room, Taizhou, Zhejiang China Announcement • Mar 31
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 31
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025 Buy Or Sell Opportunity • Nov 14
Now 21% undervalued Over the last 90 days, the stock has risen 4.4% to CN¥16.98. The fair value is estimated to be CN¥21.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 25% in a year. Earnings are forecast to grow by 388% in the next year. Buy Or Sell Opportunity • Oct 29
Now 21% undervalued Over the last 90 days, the stock has risen 2.7% to CN¥16.91. The fair value is estimated to be CN¥21.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 25% in a year. Earnings are forecast to grow by 388% in the next year. Announcement • Sep 30
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Announcement • Jun 29
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • Jun 01
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.50000000. Record date: 05 June 2024; Ex-date: 06 June 2024; Payment date: 06 June 2024. Price Target Changed • Apr 30
Price target decreased by 13% to CN¥22.60 Down from CN¥26.00, the current price target is provided by 1 analyst. New target price is 18% above last closing price of CN¥19.12. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥0.80 for next year compared to CN¥0.08 last year. Announcement • Apr 28
Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024, at 14:00 China Standard Time. Location: The Company Headquarters' Meeting Room, Taizhou, Zhejiang China Agenda: To consider 2023 work report of the board of directors; to consider 2023 work report of the supervisory committee; to consider 2023 annual report and its summary; to consider 2023 annual accounts report; to consider 2023 profit distribution plan; to consider Reappointment of 2024 audit firm; to consider 2024 estimated continuing connected transactions; to consider Remuneration for directors; to consider Remuneration for supervisors; to consider Application for bank comprehensive credit line by the Company and wholly-owned subsidiaries and provision of guarantee; to consider Launching foreign exchange hedging business; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; and to consider other matters. Announcement • Apr 27
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced on 26 April 2024 the profit distribution proposal for 2023 as follows: Cash dividend/10 shares (tax included) of CNY 0.50000000. Reported Earnings • Apr 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.08 (up from CN¥0.34 loss in FY 2022). Revenue: CN¥2.53b (down 5.2% from FY 2022). Net income: CN¥27.4m (up CN¥146.3m from FY 2022). Profit margin: 1.1% (up from net loss in FY 2022). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 81%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Announcement • Mar 30
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Jan 27
Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) announces an Equity Buyback for CNY 50 million worth of its shares. Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its shares. The shares will be repurchased at a price not more than CNY 31.3 per share. The repurchased shares will be used for employee stock ownership plan or equity incentives and if company fails to use the repurchased shares then shares will be cancelled. The shares will be repurchased from company's own funds. The authorization will be valid for a period of 6 months. Announcement • Dec 29
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.16 loss in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.002 (up from CN¥0.16 loss in 3Q 2022). Revenue: CN¥518.6m (down 15% from 3Q 2022). Net income: CN¥683.0k (up CN¥56.9m from 3Q 2022). Profit margin: 0.1% (up from net loss in 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 29
Second quarter 2023 earnings released: CN¥0.096 loss per share (vs CN¥0.029 profit in 2Q 2022) Second quarter 2023 results: CN¥0.096 loss per share (down from CN¥0.029 profit in 2Q 2022). Revenue: CN¥569.2m (down 21% from 2Q 2022). Net loss: CN¥32.1m (down 414% from profit in 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Announcement • May 26
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes Zhejiang Tianyu Pharmaceutical Co., Ltd. held its Annual General Meeting of 2022 on 22 May 2023, during which the following proposal(s) was/were approved: Election and nomination of non-independent directors, cumulative voting system applicable: Zhu Guorong, Deng Chuanliang. Election and nomination of independents, cumulative voting system applicable. Shi Jinjuan, Zhang Guoyun, Ding Hanfeng. Election and nomination of non-employee supervisors, cumulative voting system applicable: Ma Cheng, Wang Xiulin. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.29 (up from CN¥0.24 in 1Q 2022). Revenue: CN¥777.2m (up 3.6% from 1Q 2022). Net income: CN¥100.2m (up 18% from 1Q 2022). Profit margin: 13% (up from 11% in 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Price Target Changed • Nov 16
Price target decreased to CN¥25.01 Down from CN¥52.77, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of CN¥25.61. Stock is down 48% over the past year. The company is forecast to post earnings per share of CN¥0.31 for next year compared to CN¥0.59 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 7 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xin Zhao was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: CN¥0.16 loss per share (vs CN¥0.072 profit in 3Q 2021) Third quarter 2022 results: CN¥0.16 loss per share (down from CN¥0.072 profit in 3Q 2021). Revenue: CN¥610.5m (up 6.6% from 3Q 2021). Net loss: CN¥56.2m (down 321% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.029 (vs CN¥0.14 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.029 (down from CN¥0.14 in 2Q 2021). Revenue: CN¥724.0m (up 19% from 2Q 2021). Net income: CN¥10.2m (down 78% from 2Q 2021). Profit margin: 1.4% (down from 7.8% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 40%, compared to a 21% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Jul 01
Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) announces an Equity Buyback for CNY 100 million worth of its shares. Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 6 months. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥28.46, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 59% over the past three years. Announcement • Jun 07
Zhejiang Tianyu Pharmaceutical Co., Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on June 13, 2022 Zhejiang Tianyu Pharmaceutical Co., Ltd. implemented final Cash dividend (A shares) of CNY 1.00000000 per 10 shares (tax included) for 2021, payable on June 13, 2022 with Record date of June 10, 2022 and Ex-date of June 13, 2022. Announcement • May 18
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2021 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced final cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2021. Major Estimate Revision • Apr 28
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥3.44b to CN¥3.30b. EPS estimate also fell from CN¥1.57 per share to CN¥1.33 per share. Net income forecast to grow 226% next year vs 28% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥52.77 to CN¥41.47. Share price fell 11% to CN¥30.15 over the past week. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.24 (down from CN¥0.38 in 1Q 2021). Revenue: CN¥749.9m (down 1.2% from 1Q 2021). Net income: CN¥84.7m (down 37% from 1Q 2021). Profit margin: 11% (down from 18% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 19%. Over the next year, revenue is forecast to grow 38%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 7 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Hai Zhi Ren was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 24
Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2022 Zhejiang Tianyu Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2022, at 14:00 China Standard Time. Agenda: To consider the by-election of independent directors; to consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 annual report and its summary; to consider 2021 annual accounts; to consider 2021 profit distribution plan; to consider the reappointment of 2022 audit firm; to consider 2022 estimated continuing connected transactions; to consider remuneration for directors and senior management; to consider remuneration for supervisors; to consider an application for bank comprehensive credit line by the Company and wholly-owned subsidiaries and provision of guarantee; and to consider the launching foreign exchange hedging business. Announcement • Apr 23
Zhejiang Tianyu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021 Zhejiang Tianyu Pharmaceutical Co., Ltd. proposed final cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2021. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥38.30, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 80% over the past three years. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥40.44, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 225% over the past three years. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS CN¥0.072 (vs CN¥0.61 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥572.7m (down 15% from 3Q 2020). Net income: CN¥25.4m (down 87% from 3Q 2020). Profit margin: 4.4% (down from 29% in 3Q 2020). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥43.10, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 457% over the past three years. Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥49.19, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 507% over the past three years. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.66 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥608.2m (down 20% from 2Q 2020). Net income: CN¥47.2m (down 78% from 2Q 2020). Profit margin: 7.8% (down from 28% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥44.35, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 428% over the past three years. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 40% share price gain to CN¥37.99, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 331% over the past three years. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥29.17, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 155% over the past three years. Announcement • May 16
Zhejiang Tianyu Pharmaceutical Co., Ltd. Approves Cash Dividend for the 2020 Zhejiang Tianyu Pharmaceutical Co., Ltd. at its Annual General Meeting of 2020 held on 12 May 2021 approved 2020 profit distribution plan with cash dividend (tax included) of CNY 5.00000000 per 10 shares. Reported Earnings • Apr 20
First quarter 2021 earnings released: EPS CN¥0.69 (vs CN¥0.93 in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥758.9m (up 33% from 1Q 2020). Net income: CN¥133.5m (down 20% from 1Q 2020). Profit margin: 18% (down from 29% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥77.09, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 196% over the past three years. Announcement • Mar 09
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Apr 20, 2021 Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥95.00, the stock is trading at a trailing P/E ratio of 23.8x, up from the previous P/E ratio of 20.1x. This compares to an average P/E of 30x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 322%. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥84.05 The company is down 13% from its price of CN¥96.25 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥18.67 per share. Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 16% share price gain to CN¥99.99, the stock is trading at a trailing P/E ratio of 25x, up from the previous P/E ratio of 21.7x. This compares to an average P/E of 34x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 279%. Is New 90 Day High Low • Nov 13
New 90-day low: CN¥90.67 The company is down 12% from its price of CN¥103 on 14 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.73 per share. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥719.6m, up 36% from the prior year. Total revenue was CN¥2.53b over the last 12 months, up 24% from the prior year. Announcement • Oct 17
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 23, 2020 Is New 90 Day High Low • Sep 28
New 90-day low: CN¥99.89 The company is down 6.0% from its price of CN¥106 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥42.12 per share. Announcement • Aug 06
Zhejiang Tianyu Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020 Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020